Intellia Therapeutics is reportedly making steady progress, with historic commercial approval potentially on the horizon. The company has announced its first quarter 2026 financial results and business updates. It appears that a biologics license application, or BLA, has been accepted by the FDA, although it is unclear if this is directly related to Intellia Therapeutics or another company, Inhibrx.